Medtrade partners with Laubscher & Co to address postpartum haemorrhage across Switzerland
Medtrade Products Ltd is delighted to announce that it has entered into an exclusive agreement with Laubscher & Co AG to distribute the revolutionary CELOX™ PPH Uterine Haemostatic Tamponade in Switzerland. CELOX PPH offers a unique, CE-certified solution for uterine postpartum haemorrhage (PPH), and Laubscher’s network of Swiss hospitals and clinics will help more clinicians to access this vital solution to help manage postpartum bleeding.
PPH is the leading cause of maternal mortality worldwide, affecting approximately 14 million women and causing 80,000 deaths each year. However, despite the severity and prevalence of this childbirth complication, existing treatment options are limited. Therefore, CELOX PPH was designed to work rapidly and effectively in any setting, without the need for power, suction, saline or specific storage conditions. Current clinical evidence demonstrates 100 % haemostasis for grade 1 and 2 bleeding (up to 2,500 ml) in all deliveries, and 95.6 % haemostasis for up to grade 3 bleeding (8,000 ml) in vaginal deliveries, as well as a 78 % reduction in hysterectomy rates compared to the current treatment options. The efficacy of the tamponade has been documented in numerous peer-reviewed publications in leading OBGYN journals over the last 10 years.
Robert Laubscher, CEO of Laubscher, commented: “Laubscher is committed to supplying its customers with high quality medical devices that address unmet clinical needs, and we are constantly seeking innovative solutions. We recognise the high occurrence and poor clinical outcomes associated with PPH, and we are proud to enter into this agreement to progress the field of obstetrics with Medtrade, helping clinicians to overcome the limitations in current standards of postpartum care.”
Russ Mably, the Chief Executive Officer at Medtrade Products Ltd, added: “This distribution agreement aligns with Medtrade’s ambition to make CELOX PPH tamponades an essential presence at every delivery across the world. We look forward to working with Laubscher to improve obstetric outcomes in Switzerland, with the aim of significantly reducing maternal mortality rates and improving patients’ quality of life.”
For more information, please visit www.celoxpph.com or contact us at email@example.com.